TCF7L2抗体;TCF7L2 Antibody—艾普蒂

+ +

•  

   

     Western blot analysis of TCF7L2 expression in Jurkat cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human colonic cancer, using TCF7L2 Antibody.    

  
  

The TCF7L2 antibody is designed to detect transcription factor 7-like 2 (TCF7L2), a key protein in the Wnt/β-catenin signaling pathway. TCF7L2. also known as TCF4. belongs to the TCF/LEF family of transcription factors that mediate Wnt signaling by binding β-catenin to regulate target gene expression. This pathway is critical in embryonic development, cell differentiation, and metabolic homeostasis, particularly in pancreatic β-cells and liver tissues.

TCF7L2 gained prominence due to its strong association with type 2 diabetes (T2D). Genome-wide studies identified TCF7L2 as the most significant genetic risk factor for T2D, with specific single-nucleotide polymorphisms (SNPs) linked to impaired insulin secretion and glucose metabolism. Researchers use TCF7L2 antibodies to study its expression, localization, and interactions in disease models, elucidating its role in β-cell dysfunction and insulin regulation.

In cancer, TCF7L2 is implicated in colorectal and other malignancies due to Wnt pathway dysregulation. Antibodies enable detection of TCF7L2 isoforms and post-translational modifications, which influence its transcriptional activity. Common applications include Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP). However, challenges arise from TCF7L2’s multiple splice variants and homology with other TCF family members, necessitating rigorous validation using knockout controls.

Overall, TCF7L2 antibodies are vital tools for exploring its dual roles in metabolic diseases and cancer, offering insights into therapeutic targeting of Wnt signaling.